Abstract The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycaemia in type 2 diabetes in adults, published since 2006 and last updated in 2019
Lilly also has broader ambitions for orforglipron beyond obesity
The Tirzepatide segment is expected to grow at a CAGR of 12.87% during the forecast period due to its dual GIP/GLP-1 receptor mechanism, superior weight-loss efficacy demonstrated in comparative clinical studies, and expanding regulatory approvals across metabolic disease indications
Physician-supervised GLP-1 weight loss with Tirzepatide, offering personalized care in Glendale, La Caada and Burbank
A recent report from the Institute for Clinical and Economic Review, an independent nonprofit that evaluates the value of medical treatments, found that GLP-1s such as Ozempic, Wegovy and Zepbound are cost-effective, meaning the medication's health benefits justify their price